If You Cure It, Will They Pay? Placing a Value on Lives

Executive Summary

• Core Tension: The healthcare sector is at a tipping point where rapid innovation in "game-changing" therapies (e.g., Kalydeco for Cystic Fibrosis, Sovaldi for Hepatitis C) clashes with rigid budget constraints and a system incapable of absorbing upfront costs for long-term savings.
• Stakeholder Alignment: Payers, providers, and policymakers are converging on "value-based reimbursement" models, though political rhetoric often obscures the practical consensus on aligning payment with outcomes rather than volume.
• Market Shift: Regulatory approval is no longer a "green light" for market success; commercial viability now depends on demonstrating value through real-world data, total cost of care reduction, and alignment with payer utilization management strategies.

Key Facts, Data Points, and Case Studies

• Cystic Fibrosis (CF) Impact:
  • CF affects approximately 30,000 people in the U.S. and 70,000 worldwide.
  • Historically, CF was fatal before kindergarten; today, life expectancy extends to full, productive lives due to coordinated care and targeted therapies.
  • Kalydeco (2012 Launch):
    • First drug to target the genetic defect in CF rather than symptoms.
    • Cost: $309,000 annually per patient (two pills daily for life).
    • Treats only 1,000 eligible patients in the U.S.
    • Outcomes: Patients removed from lung transplant lists, able to attend medical school, and conceive children.
• Hepatitis C (Sovaldi) Case Study:
  • Gilead Sciences' Drug: Cures Hepatitis C in ~3 months with nearly 100% efficacy.
  • Pricing Strategy: $84,000 for a full course.
    • Compared to older therapies which cost ~$150,000–$200,000 total (including side effect management like blood transfusions).
    • Compared to chronic care drugs (e.g., HIV, MS), the cure is cost-effective via net present value.
  • System Friction: Payers struggle with "upfront" payment for "downstream" savings (e.g., preventing cirrhosis/liver cancer 5–15 years later).
  • Utilization Triage: Medicaid programs (e.g., Arkansas) have temporarily restricted coverage to the sickest patients, arguing the system was not budgeted for treating previously untreatable populations.
• Efficiency & Waste Data:
  • CF Care Centers: A study of five centers with identical clinical outcomes showed massive cost variances; one center's antibiotic costs were double another's due to "throwing the book" at patients unnecessarily.
  • Provider Inefficiency: CF care centers report 50% of staff time spent on reimbursement issues, with 25% of that half dedicated solely to prior authorizations.
  • Waste Identification: Medical waste is estimated at $750 billion annually within the delivery system.
• Device Cost Innovation Example:
  • Implantable defibrillators previously cost $35,000–$50,000 for preventive use.
  • "Airbag" style alternatives exist at $10,000 with adequate efficacy, but were previously underutilized because hospitals had no financial incentive to switch (they kept the savings).

Decisions, Trends, and Strategic Shifts

• Reimbursement Models Evolving:
  • Shift from fee-for-service to value-based reimbursement, bundled payments, and full capitation models where providers bear financial risk.
  • Payers are moving toward "value-based benefits," requiring patients to have "skin in the game" (higher deductibles and cost-sharing).
  • Private sector innovation in payment models (e.g., CareFirst/Blue Cross in D.C. proposing lower cost-sharing for chronic disease drugs) is outpacing government experimentation.
• Data Infrastructure as a Value Tool:
  • CF Registry demonstrates the viability of using large-scale, standardized real-world data to identify cost variances and best practices without the expense of new randomized controlled trials (RCTs).
  • Trend toward integrating electronic medical records, lab data, and administrative data to build analogous infrastructure for other disease areas.
• Collaborative Guidelines:
  • Shift from payer-imposed restrictions to "Choosing Wisely" initiatives where providers self-regulate waste (e.g., reducing unnecessary antibiotics) in exchange for reduced administrative burdens (e.g., fewer prior authorizations).
  • Payers are partnering with delivery systems (e.g., Aetna with oncology groups) to define guidelines for expensive new therapies like Sovaldi and Kalydeco.
• Investment Strategy Realignment:
  • Innovators are advised to target "focused innovation": creating products that match clinical outcomes at a lower cost (e.g., the $10k defibrillator) to capture market share under value-based contracts.
  • R&D must now anticipate post-FDA hurdles, focusing on cost-effectiveness and comparative effectiveness early in the development cycle.

Disagreements and Nuanced Debates

• The "Rationing" Debate:
  • Reed Tuckson: Argues the system is already rationing due to budget math; states like Arkansas are not ignoring value but facing "no more taxes" mandates from citizens.
  • Greg Alton (Gilead): Warns that focusing strictly on immediate cost reduction for cures sends a dangerous message to R&D, potentially stifling breakthrough therapies for diseases currently untreated (e.g., Alzheimer's) where no baseline cost exists to offset.
  • Shami Fineglas: Notes that triage is a natural adjustment to volume spikes but cautions against allowing socioeconomic status to become the sole determinant of access to cures.
• Political Landscape:
  • Dean Rosen: Highlights that while partisan mudslinging continues regarding the Affordable Care Act (ACA), key congressional committees have bipartisan consensus on moving toward value-based physician payments.
  • Sean Tunis: Observes that Congress avoids direct rationing discussions ("magic" thinking), preferring to set frameworks and let providers/payers navigate the trade-offs.
• Definition of Value:
  • Current State: Measures often focus on survival duration rather than quality of life.
  • Proposed Shift: Measures must evolve to include patient voices and quality-of-life metrics to avoid "innovation for innovation's sake" without systemic impact.

Forward-Looking Statements and Predictions

• Micromanagement vs. Trust: Payers will likely tighten controls on high-cost treatments unless providers can demonstrate quality and cost-effectiveness through shared data; rural areas with no alternative care options may face unique political challenges if centers are closed for inefficiency.
• Prevention as an Innovation Driver: Significant economic opportunity exists in preventative measures (e.g., Hepatitis C prevention) to stop the "spigot" from turning on, rather than just curing the disease.
• Payer-Provider Alliances: Unusual alliances will form between health plans and delivery systems to navigate cost pressure, moving away from adversarial relationships toward shared risk and reward structures.
• Regulatory Evolution: FDA approval will remain necessary but insufficient; future regulatory and reimbursement frameworks will require "value proof" at the outset of development, not just safety and efficacy.
• Market Consolidation: Delivery systems that cannot demonstrate cost efficiency or quality outcomes relative to peers may face economic attrition or closure, particularly in non-competitive markets.